Finance

Beta
Lists
JNJ:NYSE
Johnson & Johnson
$225.33
-2.37%
(-5.47) 1D
May 29, 4:00:06 PM GMT-4  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for JNJ...
Open
$231.23
High
$231.50
Low
$224.58
Mkt. cap
542.42B
Avg. vol.
7.67M
Volume
0.00
Dividend
2.38%
Quarterly dividend
$1.34
Ex-dividend date
May 26, 2026
P/E ratio
26.06
52-wk high
$251.71
52-wk low
$149.04
EPS
$8.65
Beta
0.27
Shares outstanding
2.41B
No. of employees
138K
Open
$231.23
High
$231.50
Low
$224.58
Mkt. cap
542.42B
Avg. vol.
7.67M
Volume
0.00
Dividend
2.38%
Quarterly dividend
$1.34
Ex-dividend date
May 26, 2026
P/E ratio
26.06
52-wk high
$251.71
52-wk low
$149.04
EPS
$8.65
Beta
0.27
Shares outstanding
2.41B
No. of employees
138K
News stories
From sources across the web
Profile
Johnson & Johnson is an American multinational pharmaceutical, biotechnology, and medical technologies corporation headquartered in New Brunswick, New Jersey. The company operates 2 divisions: Innovative Medicine and MedTech. Major products produced by the Innovative Medicine division are CARVYKTI for multiple myeloma; DARZALEX, also for multiple myeloma; ERLEADA, for prostate cancer; REMICADE, for inflammatory diseases; SIMPONI/SIMPONI ARIA, for rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, and polyarticular juvenile idiopathic arthritis; STELARA, for plaque psoriasis, psoriatic arthritis, Crohn's disease, and ulcerative colitis; TREMFYA, for plaque psoriasis, psoriatic arthritis, Crohn’s disease, and ulcerative colitis; INVEGA SUSTENNA/XEPLION, for schizophrenia; SPRAVATO, a nasal spray for depression; OPSUMIT /OPSYNVI for pulmonary arterial hypertension; and UPTRAVI for pulmonary arterial hypertension. The MedTech division produces products used for cardiovascular, orthopaedics, surgery, and vision treatments. The company is ranked 48th on the Fortune 500 and 42nd on the Forbes Global 2000. Wikipedia
About Johnson & Johnson
CEOJoaquin Duato
Employees138K
FoundedJan 1886
HeadquartersNew Brunswick, New Jersey, United States
SectorPharmaceutical industry
Websitejnj.com
Last report
Apr 14, 2026
Fiscal period
Q1 2026
EPS / Est. (USD)
$2.70 / $2.68
+0.85%beat
Revenue / Est. (USD)
24.06B / 23.61B
+1.89%beat
Fiscal Q1 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Income statement
Revenue
Net income
All values in USD
Jun 2025
Sep 2025
Dec 2025
Mar 2026
Revenue
23.74B
23.99B
24.56B
24.06B
Cost of goods sold
7.61B
7.29B
7.81B
8.09B
Cost of revenue
7.61B
7.29B
7.81B
8.09B
Research and development expenses
3.52B
3.67B
4.25B
3.53B
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
5.75B
5.78B
6.61B
5.85B
Operating expense
9.27B
9.46B
10.86B
9.38B
Total operating expenses
16.88B
16.75B
18.68B
17.47B
Operating income
6.86B
7.25B
5.89B
6.60B
Other non operating income
207.00M
17.00M
396.00M
-211.00M
EBT including unusual items
6.49B
7.49B
4.97B
5.99B
EBT excluding unusual items
6.97B
7.27B
6.03B
6.41B
Income tax expense
954.00M
2.34B
-150.00M
755.00M
Effective tax rate
14.70%
31.24%
-3.02%
12.60%
Other operating expenses
-
-
-
-
Net income
5.54B
5.15B
5.12B
5.24B
Net profit margin
23.32%
21.47%
20.83%
21.76%
Earnings per share
2.77
2.80
2.46
2.70
Interest and investment income
260.00M
227.00M
237.00M
229.00M
Interest expense
-308.00M
-245.00M
-214.00M
-272.00M
Net interest expenses
-48.00M
-18.00M
23.00M
-43.00M
Depreciation and amortization charges
-
-
-
-
EBITDA
8.81B
9.02B
7.90B
8.60B
Gain or loss from assets sale
1.00M
-57.00M
-132.00M
12.00M
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer

Research

AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer